Rydex Biotechnology Inv holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Rydex Biotechnology Fund Class Investor RYOIX
- NAV / 1-Day Return 80.54 / +2.44 %
- Total Assets 107.7M
-
Adj. Expense Ratio
1.390%
- Expense Ratio 1.390%
- Distribution Fee Level Above Average
- Share Class Type No Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 79%
USD | NAV as of Jun 12, 2026 | 1-Day Return as of Jun 12, 2026, 12:38 AM GMT+0
Morningstar’s Analysis RYOIX
Will RYOIX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the RYOIX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of RYOIX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 36.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 7.29 | 10M | Healthcare |
Gilead Sciences Inc | 5.15 | 7M | Healthcare |
Amgen Inc | 5.14 | 7M | Healthcare |
Vertex Pharmaceuticals Inc | 4.54 | 6M | Healthcare |
Regeneron Pharmaceuticals Inc | 3.48 | 5M | Healthcare |
Alnylam Pharmaceuticals Inc | 2.45 | 3M | Healthcare |
BeOne Medicines Ltd ADR | 2.29 | 3M | Healthcare |
Natera Inc | 2.27 | 3M | Healthcare |
AstraZeneca PLC ADR | 2.23 | 3M | Healthcare |
Biogen Inc | 2.12 | 3M | Healthcare |
United States